Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer

Chu, Jinjin; Fang, Xianzhu; Sun, Zhenkun; Gai, Linlin; Dai, Wenqing; Li, Haibo; Yan, Xinyi; Du, Jinke; Zhang, Lili; Zhao, Lu; Xu, Dongmei; Yan, Shushan

doi:10.3389/fonc.2021.801319

Cited by 6 publications

(7 citation statements)

References 109 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, some lncRNAs can be processed to generate miRNAs that negatively regulate target mRNAs [ 41 ], and lncRNAs and circRNAs can act as a ceRNA to competitively bind to miRNAs and eliminate the inhibition of target genes [ 29 , 31 ]. Chu et al have reviewed the advance of ncRNAs in anti-EGFR mAbs therapy resistance [ 190 ]. In this paper, we conducted a more comprehensive search and update of relevant literature, which not only included more reports of ncRNAs related to anti-EGFR resistance, but also demonstrated the interaction networks between different ncRNAs, providing more detailed and in-depth mechanism exploration and researches on reversal of Cetuximab resistance.…”

Section: Discussion and Prospectmentioning

confidence: 99%

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Wei

Feng

et al. 2022

Cell Commun Signal

View full text Add to dashboard Cite

Anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibodies (mAbs) are of great significance for RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients. However, the generation of primary and secondary resistance to anti-EGFR mAbs has become an important factor restricting its efficacy. Recent studies have revealed that non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are implicated in anti-EGFR antibodies resistance, affecting the sensitivity of CRC cells to Cetuximab and Panitumumab. This paper briefly reviewed the research advance of the expression, signaling network and functional mechanism of ncRNAs related to anti-EGFR mAbs resistance in CRC, as well as their relationship with clinical prognosis and the possibility of therapeutic targets. In addition, some ncRNAs that are involved in the regulation of signaling pathways or genes related to anti-EGFR resistance, but need to be further verified by resistance experiments were also included in this review, thereby providing more ideas and basis for ncRNAs as CRC prognostic markers and anti-EGFR therapy sensitizers.

show abstract

Section: Discussion and Prospectmentioning

confidence: 99%

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Wei

Feng

et al. 2022

Cell Commun Signal

View full text Add to dashboard Cite

show abstract

“…Moreover, the high expression of exosomal miR-92a-3p in serum predicts metastasis and chemotherapy resistance in CRC patients[ 24 ]. The overexpression of miR-100, miR-125b, miR-27a, miR-135, and MIR100HG in CRC tumors modulates the canonical Wnt pathway, promoting events such as proliferation and invasion[ 71 , 72 ].…”

Section: Tme Factors and Conditions That Modulate The Wnt/β-catenin P...mentioning

confidence: 99%

“…Two years earlier, Fang and his group revealed that circ_100290 promotes CRC progression through activation of the Wnt/β-catenin pathway[ 74 ]. Other cRNAs involved in the activation of this signaling pathway in CRC are Hsa_circ_0005075[ 75 ], circMTO1[ 76 ] and Circ-PRKDC[ 72 ]. On the other hand, cRNAs such as circPRKDC and cirITCH act by inhibiting the activity of the β-catenin pathway[ 77 , 78 ].…”

Section: Tme Factors and Conditions That Modulate The Wnt/β-catenin P...mentioning

confidence: 99%

Tumor microenvironment involvement in colorectal cancer progression via Wnt/β-catenin pathway: Providing understanding of the complex mechanisms of chemoresistance

Díaz¹,

Martín²,

Gentili³

2022

WJG

View full text Add to dashboard Cite

Colorectal cancer (CRC) continues to be one of the main causes of death from cancer because patients progress unfavorably due to resistance to current therapies. Dysregulation of the Wnt/β-catenin pathway plays a fundamental role in the genesis and progression of several types of cancer, including CRC. In many subtypes of CRC, hyperactivation of the β-catenin pathway is associated with mutations of the adenomatous polyposis coli gene. However, it can also be associated with other causes. In recent years, studies of the tumor microenvironment (TME) have demonstrated its importance in the development and progression of CRC. In this tumor nest, several cell types, structures, and biomolecules interact with neoplastic cells to pave the way for the spread of the disease. Cross-communications between tumor cells and the TME are then established primarily through paracrine factors, which trigger the activation of numerous signaling pathways. Crucial advances in the field of oncology have been made in the last decade. This Minireview aims to actualize what is known about the central role of the Wnt/β-catenin pathway in CRC chemoresistance and aggressiveness, focusing on cross-communication between CRC cells and the TME. Through this analysis, our main objective was to increase the understanding of this complex disease considering a more global context. Since many treatments for advanced CRC fail due to mechanisms involving chemoresistance, the data here exposed and analyzed are of great interest for the development of novel and effective therapies.

show abstract

“…Recent studies have revealed that abnormal expressions of long non-coding RNAs (lncRNAs), which are RNAs longer than 200 nucleotides and without the ability to code for proteins, are linked to the occurrence, progression, recurrence, metastasis, and chemoresistance of CRC, which can assist in diagnosis, determining prognosis, and providing therapeutic targets in CRC [ 7 , 8 , 9 , 10 ]. The lncRNAs are often expressed at lower levels but show more cell type-specific expression patterns than protein-coding genes [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Long Non-Coding RNAs Induced by the Gut Microbiome on Regulating the Development of Colorectal Cancer

Fan

Xing

Jiang

et al. 2022

Cancers

View full text Add to dashboard Cite

Although an imbalanced gut microbiome is closely associated with colorectal cancer (CRC), how the gut microbiome affects CRC is not known. Long non-coding RNAs (lncRNAs) can affect important cellular functions such as cell division, proliferation, and apoptosis. The abnormal expression of lncRNAs can promote CRC cell growth, proliferation, and metastasis, mediating the effects of the gut microbiome on CRC. Generally, the gut microbiome regulates the lncRNAs expression, which subsequently impacts the host transcriptome to change the expression of downstream target molecules, ultimately resulting in the development and progression of CRC. We focused on the important role of the microbiome in CRC and their effects on CRC-related lncRNAs. We also reviewed the impact of the two main pathogenic bacteria, Fusobacterium nucleatum and enterotoxigenic Bacteroides fragilis, and metabolites of the gut microbiome, butyrate, and lipopolysaccharide, on lncRNAs. Finally, available therapies that target the gut microbiome and lncRNAs to prevent and treat CRC were proposed.

show abstract

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer

Cited by 6 publications

References 109 publications

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

Tumor microenvironment involvement in colorectal cancer progression via Wnt/β-catenin pathway: Providing understanding of the complex mechanisms of chemoresistance

Effects of Long Non-Coding RNAs Induced by the Gut Microbiome on Regulating the Development of Colorectal Cancer

Contact Info

Product

Resources

About